9820 Global X China Biotech ETF
Solactive China Biotech NR CNH

NAV as of

0.0000

4 Week: 7.96 - 8.80

52 Week: 7.96 - 18.20

Latest Closing Price

8.44

Premium / Discount

0

Expense Ratio

0.68%

Investment Objective

The ETF seeks to provide investment results that, before deduction of fees and expenses, closely correspond to the performance of the Solactive China Biotech Index NTR.

Main Fund Characteristics

Fund Manager:
Mirae Asset Global Investments (HK) Ltd
Asset Under Management:
800,189,149
Launch Date:
N.A
Asset Class:
Equity
Replication Method:
Physical-Full
Number of Holdings:
31
Trading Currency:
USD
Style:
Large Growth
Region/Sector/Strategy:
N.A / N.A / N.A
Exchange:
HKEX

Performance

Period Performance Returns(%) Volatility(%) Risk Adjusted Performance
YTD-36.042.71-13.29
1 Day-4.390.000.00
1 Week0.006.660.00
1 Month-8.8212.34-0.71
3 Months-21.1624.25-0.87
6 Months-41.7328.41-1.47
1 Year-53.0837.61-1.41
2 Years0.000.000.00
3 Years0.000.000.00
5 Years0.000.000.00
10 Years0.000.000.00

Price History

-

Annual Performance Return

2012201320142015201620172018201920202021
Price (%) 0.00000.00000.00000.00000.00000.00000.00000.000069.6975-19.6517
Nav (%) 0.00000.00000.00000.00000.00000.00000.00000.00000.00000.0000
Rank 0.00000.00000.00000.00000.00000.00000.00000.00003.000082.0000

Dividend Frequency

Lastest Dividend

Ex Date Payment Date Dividend Payout per unit
N.A

Portfolio Data

Total Number of Holdings: 31

Number of Bond Holdings: 0

Number of Equity Holdings: 30

Total Market Value: 800,189,149

Portfolio Composition

Top 10 Holdings

% Portfolio Weight Shares Owned Shares Changed Market Value
1Wuxi AppTec Co Ltd Class A10.6172871,271084,957,635
2Walvax Biotechnology Co Ltd Class A9.52561,594,285076,222,766
3Jiangsu Hengrui Pharmaceuticals Co Ltd Class A8.00772,128,796064,076,760
4WuXi Biologics (Cayman) Inc7.86981,320,240062,973,526
5BeiGene Ltd ADR7.367565,523058,954,170
6Sino Biopharmaceutical Ltd5.091011,146,401040,737,515
7Innovent Biologics Inc4.51061,887,538036,093,155
8Shanghai Junshi Biosciences Co Ltd Class A4.1665311,587033,339,809
9Genscript Biotech Corp Class H3.65501,539,762029,247,195
10Zai Lab Ltd ADR Repr 1 Shs3.5931116,519028,751,452

Country Exposure

Regional Exposure

America

Greater Europe

Greater Asia

Market Classification

Market Capitalization

Size% of portfolio
Giant29.34
Large48.99
Medium17.87
Small3.66
Micro0.00

Equity Style Box Breakdown

000Large
000Mid
000Small
ValueBlendGrowth

Value Measures

Price/Prospective Earnings*

14.9111

Price/Book*

3.3109

Price/Sales*

4.0676

Price/Cash Flow*

20.4163

Dividend Yield*

1.0686

Growth Measures

Long-Term Earnings

445.7180

Historical Earnings

36.2849

Sales Growth

25.9401

Cash-Flow Growth

23.2778

Book-Value Growth

18.3762

*Forward-looking based on historical data.

Equity Sector

Number of Bond Holdings

0

Bond Statitics

DetailValue
Average Effective Duration0
Average Effective Maturity (Years)*0
Average Credit Quality0
Average Weighted Coupon*0
Average Weighted Price*0

Bond Style Box Breakdown

000HighQuality
000Med
000Low
LtdModExt
Interest-Rate Sensitivity

Credit Quality

Type% Bonds
N.A

Bond Sector

Type
% Bonds

Bond Maturity

% Bonds
N.A

Data Source: Morningstar

© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:

(1) include the proprietary information of Morningstar and Morningstar’s third party licensors;
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.

Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.